Board Change • Jul 28
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Vanni Barbon was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jul 09
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Vanni Barbon was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • May 12
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Vanni Barbon was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 15
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Vanni Barbon was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Mar 05
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Vanni Barbon was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jan 29
Pegasus Mercantile Inc. (CNSX:LOAN) signed a non-binding letter of intent to acquire Omega Gold Corp. Pegasus Mercantile Inc. (CNSX:LOAN) signed a non-binding letter of intent to acquire Omega Gold Corp. on January 28, 2026. Pegasus Mercantile will have a 30-day due diligence period with a deadline of February 28, 2026 to sign a definitive agreement subject to the CSE and regulatory approvals. Board Change • Dec 31
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Vanni Barbon was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 11
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Vanni Barbon was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Oct 07
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Vanni Barbon was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Sep 23
Pegasus Mercantile Inc. (CNSX:LOAN) agreed to acquire Independent Retailers Alliance Inc. for CAD 2 million. Pegasus Mercantile Inc. (CNSX:LOAN) agreed to acquire Independent Retailers Alliance Inc. for CAD 2 million on September 22, 2025. The consideration consists of common equity of Pegasus Mercantile Inc. having a value of CAD 2 million to be issued for common equity of Independent Retailers Alliance Inc. Additionally, financing up to CAD 1 million will be announced with terms to be discussed. Alliance shall have the right to appoint one
individual to the board of directors of the Company, in the first quarter of 2026 subject to the Company board and regulatory approval of the individual.
The expected completion of the transaction is October 15, 2025, subject to CSE acceptance. Board Change • Sep 17
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Vanni Barbon was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Aug 21
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Vanni Barbon was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jul 25
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Vanni Barbon was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Jun 22
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$624k). Revenue is less than US$1m. Market cap is less than US$10m (CA$66.8k market cap, or US$48.6k). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding). Board Change • Apr 24
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Vanni Barbon was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Mar 14
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Vanni Barbon was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Feb 25
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Vanni Barbon was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Oct 09
Xtacy Therapeutics Corp. Announces Board Changes Xtacy Therapeutics Corp. announced updates to its Board of Directors. Ashleigh Vogstad is stepping down from the Board, and Vanni Barbon has been appointed as a Director and the new Audit Chair. Mr. Barbon's professional experience is extensive; as a BMO Commercial Branch Manager, Investment Analyst, and a public company Chief Financial Officer. Announcement • Apr 03
Xtacy Therapeutics Corp. to Report Q1, 2024 Results on Apr 17, 2024 Xtacy Therapeutics Corp. announced that they will report Q1, 2024 results on Apr 17, 2024 New Risk • Mar 10
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (73% average weekly change). Negative equity (-CA$570k). Revenue is less than US$1m. Market cap is less than US$10m (CA$4.09m market cap, or US$3.03m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (38% increase in shares outstanding). Announcement • Dec 08
Xtacy Therapeutics Corp. Expands MDMA Platform Pharmaceutical Grade Psychedelic Solutions to Solve Unmet Medical Needs Xtacy Therapeutics Corp. announces expansion of its MDMA research platform to help find solutions to unmet medical needs focused on Perioperative Pain, Social Anxiety Disorder, Hypoactive Sexual Desire Disorder and Anorexia Nervosa. The Company is expanding its' MDMA research platform to pursue financing for clinical trials to include Perioperative Pain, but also Social Anxiety Disorder, Hypoactive Sexual Desire Disorder (HSDD) and Anorexia Nervosa. There is existing evidence for efficacy in all four indications from studies on MDMA. Leapfrogging some development phases became obvious from the extensive data available from MAPS for both safety and efficacy. This should eliminate the need for additional preclinical, Phase 1 trials - bibliographic data utilization and allow for an accelerated entry into Phase 2 and Phase 3 trials, saving both time and financial resources to the Company. Board Change • Oct 25
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Ashleigh Vogstad was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • May 13
Global Wellness Strategies Inc., Annual General Meeting, Jul 13, 2023 Global Wellness Strategies Inc., Annual General Meeting, Jul 13, 2023. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Ashleigh Vogstad was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Ashleigh Vogstad was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Jun 18
Global Wellness Strategies Inc., Annual General Meeting, Aug 18, 2022 Global Wellness Strategies Inc., Annual General Meeting, Aug 18, 2022. Announcement • May 13
Global Wellness Strategies Inc. Announces Shanti Therapeutics Mdma Clinical Trial Update Global Wellness Strategies Inc. announced Shanti Therapeutics MDMA Clinical Trial Update. Shanti's product suite of MDMA could be the global market winner finding a solution to the chronic puzzle of pain. iNGENü a subsidiary of Australian leader Cannvalate is engaged as the CRO (clinical research organization) by the Company to conduct clinical trials for Shanti Therapeutics. The protocol is a single center, randomized crossover study to investigate the efficacy of MDMA vs placebo in a model of experimental pain in healthy adults. Shanti has a targeted research pathway to clinical success, with strong proprietary protection under its already submitted patent providing a method for the treatment or prevention of pain. The Shanti Key Opinion Leader (KOL) Dr. Michael Keane who is a specialist anesthesiologist announced in November 2021, has already assembled the Shanti team with a wealth of data to support the potential development of a new generation of drugs to help patients suffering from chronic pain. He is the author of multiple MDMA articles, published in peer-reviewed scientific journals. As previously announced in November 2021, Shanti submitted an application to Swinburne University (Melbourne, Australia) to the University Institutional Review Board (IRB) or HREC committee. The purpose of the HREC (Human Research Ethics Committee) review is to ensure that all clinical trials are conducted in accordance with Good Clinical Practice (GCP) and pose minimal safety concerns for the trial participants. iNGENü on behalf of Shanti as the sponsor of the trials, will begin the selection of the 22 healthy volunteers shortly in Australia for the trial; comparing the pain tolerance threshold in patients who have had exposure to a proprietary dose and formulation of MDMA. iNGENü signed a supply agreement in February 2022 with Canada-based PharmAla Biotech to supply MDMA for the Shanti Therapeutics upcoming clinical trial and will disclose receipt of MDMA when appropriate. The Company is excited to be working with iNGENü and Shanti on the development of a novel drug to be used in the treatment of perioperative pain. Psychosocial elements can exacerbate the perception of pain but similarly, pain can often have significant psychological sequelae and lead to prolonged mental health issues. Depression, anxiety and other mental health issues often coexist with pain syndromes by the time they present to the treating physician. Announcement • May 10
Global Wellness Strategies Inc. Announces Appointment of Sud Agarwal as the Chief Medical Advisor Global Wellness Strategies Inc. announced appointment of Dr. Sud Agarwal as the chief medical advisor to lead the advisory team. His experience and expertise in the psychedelic industry will contribute significantly to efforts in the space moving forward. Dr. Agarwal is a co-founder of Shanti Therapeutics based in Australia, a company focused on pharmaceutical grade psychedelic solutions that Global Wellness recently acquired from Cannvalate Pty Ltd. Shanti is focused on psychedelic MDMA-based drug development and solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. Announcement • Apr 13
Global Wellness Strategies Inc. Announces Their Brand KaleidoMyco to Launch Their Proprietary Fizz Tablets Global Wellness Strategies Inc. announced that their brand KaleidoMyco will be launching their proprietary fizz tablets this month to the American marketplace. KaleidoMyco has developed the first-ever dissolvable hemp infused myco tablets to enter the effervescent category. The tablets dissolve quickly in a glass of water or any beverage hot or cold, adding effervescence and flavor, and are an excellent way to supplement a healthy diet with an array of complementary and synergistic ingredients. The first 3 SKUs are a combo 1+1 of 25mg cannabinoids plus 25mg of functional mushrooms flavored by natural citrus, berry and grape. Announcement • Mar 03
Global Wellness Strategies Inc. Announces Executive Changes Global Wellness Strategies Inc. announced that it has appointed Mr. Lindsey Perry JR as chief financial officer of the company. The appointment of Lindsey R. Perry JR, as CFO to the company in addition to his Directorship is in keeping with the corporate initiative in developing an international footprint. Mr. Perry was born and raised in New England, north of Boston and relocated to South Florida from Nantucket in 2005. Mr. Perry's family is credited as being one of the pioneering families to develop the Island of Nantucket as the premier vacation destination on the eastern seaboard of the United States. Mr. Stephen Brohman has resigned as the company's CFO but will remain on as a consultant for the company. Announcement • Feb 24
Global Wellness Strategies Inc. announced that it expects to receive CAD 3 million in funding Global Wellness Strategies Inc. announced a private placement of non brokered private placement of units for gross proceeds of up to CAD 3,000,000. Each unit consists of one common share and one common share purchase warrant. Each whole warrant will entitle the holder to purchase, for a period of 3 years from the date of issue, one additional common share of the issuer at an exercise price of CAD 0.30 per common share. The warrants are subject to an acceleration provision in favour of the company in the event that the shares trade on a recognized exchange at more than CAD 0.45 for a 14-day period, which can include days where no shares trade. No finder’s fees were paid in connection with the placement.
On the same date, the company announced that it has issued 2,977,779 units at a price of CAD 0.18 per unit for gross proceeds of CAD 588,500 in its first tranche. Announcement • Feb 19
Global Wellness Strategies Inc. Announces the Addition of Two International Pedigreed Senior Advisors to Its Team and the Appointment of Meris Kott to the Board of Shanti Therapeutics Global Wellness Strategies Inc. announced the addition of two International Pedigreed Senior Advisors to its team and the appointment of Meris Kott to the board of Shanti Therapeutics. Shanti Therapeutics is focused on finding a solution to chronic pain with Psychedelics using MDMA. Global Wellness Strategies' advisory hires across pharma, product and business development, investment banking and sales are in place to support Shanti Therapeutics as a first-in-class biotech utilizing the neuromodulation properties of MDMA (aka Ecstasy) to pre-emptively treat preoperative pain. Shanti has commenced a path to their clinical trial in 22 healthy volunteers comparing the pain tolerance threshold in patients who have had exposure to a proprietary dose and formulation of MDMA. This proof-of-concept clinical study is to gauge the effect size of an increase in the pain threshold in subjects who have been pre-emptively treated with MDMA. Darryl Davies (B.Sc.) is a global leader and a founder of Shanti Therapeutics and has over 15 years experience in healthcare and in the medicinal cannabis industry with a strong background in psychology, harm minimization and medicinal cannabis regulatory. He has facilitated and executed meaningful relationships with public and private global cannabis licensed producers, biotech, and research institutions. He coordinated the execution of Australia's first leadership program for the cannabis industry in partnership with Deakin University and the University of Western Sydney. He is the co-founder of private Australian award-winning cannabis company, Cannvalate, specializing in the late part of the cannabis value chain; appointed Australia's only Director for Canadian manufacturing powerhouse, The Valens Company; Director of New Zealand's Greenfern Industries Ltd.; and Australia's InhaleRx Ltd. Shiry Eden (MBA) is CEO and Founder at NISHOT, a strategy and analysis firm focusing on the global cannabis and psychedelic industries. In 2022 she founded the Israeli cannabis and psychedelic magazine "Cannabis Capital". Since 2018, Shiry is a partner in an Israeli-global oriented mutual fund "SELA CANNABIS". She has over 20 years of experience as an economist and strategic advisor for medium to large-scale corporates in Israel, with expertise in the capital market. Prior to the establishment of Nishot, she founded and managed Eden Communications and LivingGift, served as a corporate communications manager in the second largest investment house in Israel, media advisor for the Minister of Defense, and an economist in the Budget Department of the Ministry of Defense. Announcement • Mar 05
Global Wellness Strategies Inc. Unveils First New Product for KaleidoUSA Hemp Extract Infused Myco Effervescent Global Wellness Strategies Inc. unveils the first new product for KaleidoUSA; hemp extract infused myco effervescent. KaleidoUSA to introduce their first-ever dissolvable hemp extract infused myco tablets to enter the effervescent category. The tablets dissolve quickly in a glass of water, adding effervescence and flavor, and are an excellent way to supplement a healthy diet with an array of complementary and synergistic ingredients. KaleidoUSA's new IP formula creates an on-the-go option for myco hemp-derived consumer products that promote optimal wellness. KaleidoUSA will manufacture all its products at Intercontinental Hemp LLC. based in Washington State. Intercontinental is optimizing its existing extraction equipment for the functional mushroom products. It has a state CBD processing license and meets FDA food grade and GMP pharma standards, and has the ability to ship nationwide as well as to other countries where hemp extract is approved. Announcement • Feb 04
Global Wellness Strategies Inc. announced that it expects to receive CAD 1 million in funding Global Wellness Strategies Inc. (CNSX:LOAN) announced a non-brokered private placement of up to 4,000,000 common shares at a price of CAD 0.25 per share for gross proceeds of CAD 1,000,000 on February 2, 2021. All securities are subject to a four-month holding period form the date of issue. The offering is subject to the approval of the Canadian Securities Exchange and may be closed in one or more tranches. Finders' fees may be paid to eligible finders of up to 8% in cash and 8% in finders' warrants. Each finder's warrants hall be exercisable for a common share at a price of CAD 0.35 for a period of two years from the issue date and will be subject to an accelerated expiry provision. Announcement • Jan 29
Global Wellness Strategies Inc. announced that it expects to receive CAD 2.5 million in funding from Entheotech Global Wellness Strategies Inc. (CNSX:LOAN) announced a private placement of a non-convertible promissory note for gross proceeds of CAD 2,500,000 on January 27, 2021. The transaction will include participation from Entheotech. Announcement • Jan 14
Redfund Capital Corp. Partners with Clarion Holdings of Eugene, Oregon to Open One of the First Psilocybin Consulting Incubators in the Area Redfund Capital Corp. announced that it has partnered with Clarion Holdings of Eugene, Oregon to open one of the first psilocybin consulting incubators in the area. The team has assembled a formidable group of analysts consisting of homeopathic doctors, psychiatrists, cultivators and processors. Clarion Holdings has licenses in both cannabis and hemp, and they will partner together in their submission to be one of the first psilocybin applications in the state. As well, the firm will apply to become a white label processor of approved products. Oregon is only in the preliminary stage of organizing a board of advisors representing the passed initiative but being first and ready is important. In November 2020 Oregon became the first state in the nation to legalize psilocybin in therapeutic settings. Measure 109 passed with 56% of the vote and it will be at least two years before psilocybin therapy is available in a therapeutic setting. Currently, there are no such policies in place anywhere else in the U.S.; nonetheless, there is a growing national movement to decriminalize psilocybin plus a wide range of entheogenic substances, including ayahuasca and ibogaine. Activists and health professionals in Washington State are pursuing legal psilocybin initiatives as well but the Right to Try mushroom is still in its infancy. Announcement • Nov 18
Redfund Client Cannaforum Advances to Final 20 for Dutch Cannabis License BK Capital Joins Team as Capital Markets Expert Redfund Capital Corp. announce CannaForum BV "CANNA" as newest portfolio client, updates it has made it to the last 20 applicants in the selection process by the Dutch government for the first legal cannabis cultivator licenses ever in the Netherlands. Additionally, Redfund has entered into a consulting agreement with BK Capital Partners Inc. to provide capital market advisory services to the Company. 
